-
Equivalent to the 5
TU dose recommended as
clinically established and
standardized with PPD-S
-
The result is read 48
to 72 hours later by a
healthcare professional and
induration only is
considered in interpreting the
test.
DESCRIPTION
Aplisol (tuberculin PPD, diluted) is
a sterile aqueous solution of a
purified protein fraction for
intradermal administration as an aid
in the diagnosis of tuberculosis.
The solution is stabilized with
polysorbate (Tween) 80, buffered
with potassium and sodium phosphates
and contains approximately 0.35%
phenol as a preservative. This
product is ready for immediate use
without further dilution.
Indications and Usage
Tuberculin PPD is recommended by the
American Lung Association as an aid
in the detection of infection with
Mycobacterium tuberculosis. The
standard tuberculin test recommended
employs the intradermal (Mantoux)
test using a 5 TU dose of tuberculin
PPD.7 The 0.1-mL test
dose of Aplisol (tuberculin PPD,
diluted) is equivalent to the 5 TU
dose recommended as clinically
established and standardized with
PPD-S. Tuberculin skin testing is
not contraindicated for persons who
have been vaccinated with BCG and
the skin-test results of such
persons are used to support or
exclude the diagnosis of M.
tuberculosis infections.4
HIV infection is a strong risk
factor for the development of TB
disease in persons having TB
infection. All HIV-infected persons
should receive a PPD-tuberculin skin
test.3
CONTRAINDICATIONS
Aplisol is
contraindicated in patients with
known hypersensitivity or allergy to
Aplisol or any of its components.
Aplisol should not be administered
to persons who have previously
experienced a severe reaction (e.g.,
vesiculation, ulceration, or
necrosis) because of the severity of
reactions that may occur at the test
site.
Warnings
Not all infected persons will have a
delayed hypersensitivity reaction to
a tuberculin test. A number of
factors have been reported to cause
a decreased ability to respond to
the tuberculin test, such as the
presence of infections, viral
infections (measles, mumps,
chickenpox, HIV), live virus
vaccinations (measles, mumps,
rubella, oral polio, varicella and
yellow fever), bacterial infections
(typhoid fever, brucellosis, typhus,
leprosy, pertussis, overwhelming
tuberculosis, tuberculous pleurisy),
fungal infections (South American
blastomycosis), drugs
(corticosteroids and other
immunosuppressive agents), metabolic
derangements (chronic renal
failure), low protein states (severe
protein depletion, afibrinogenemia),
age (newborns, elderly patients with
waned sensitivity), stress (surgery,
burns, mental illness,
graft-versus-host reactions),
diseases affecting lymphoid organs
(Hodgkin’s disease, lymphoma,
chronic leukemia, sarcoidosis), and
malignancy.7,8,9
Any condition that impairs or
attenuates cell mediated immunity
potentially can cause a false
negative reaction, including aging.
10,11
Tuberculin skin test results are
less reliable in HIV-infected
individuals as CD4 counts decline
(see CLINICAL PHARMACOLOGY).3
Avoid injecting tuberculin
subcutaneously. If this occurs, no
local reaction develops, but a
general febrile reaction and/or
acute inflammation around old
tuberculous lesions may occur in
highly sensitive individuals.
ADVERSE REACTIONS
In highly sensitive
individuals, strongly positive
reactions including vesiculation,
ulceration or necrosis may occur at
the test site; however, there were
no reports of these reactions for
the period 1995 through 1998. Cold
packs or topical steroid
preparations may be employed for
symptomatic relief of the associated
pain, pruritus and discomfort.
Strongly
positive test reactions may result
in scarring at the test site.
Immediate erythematous or other
reactions may occur at the injection
site.
Please see the full prescribing
information link above for
additional information and
references.